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Cancer is a complex disease that causes the alterations in the levels of gene, RNA, protein and metabolite. With the
development of genomics, transcriptomics, proteomics and metabolomic techniques, the characterisation of key
mutations and molecular pathways responsible for tumour progression has led to the identification of a large
number of potential targets. The increasing understanding of molecular carcinogenesis has begun to change
paradigms in oncology from traditional single-factor strategy to multi-parameter systematic strategy. The
therapeutic model of cancer has changed from adopting the general radiotherapy and chemotherapy to
personalised strategy. The development of predictive, preventive and personalised medicine (PPPM) will allow
prediction of response with substantially increased accuracy, stratification of particular patient groups and eventual
personalisation of medicine. The PPPM will change the approach to tumour diseases from a systematic and
comprehensive point of view in the future. Patients will be treated according to the specific molecular profiles that
are found in the individual tumour tissue and preferentially with targeted substances, if available.
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Introduction
Cancer is a complex disease that is caused by the inter-
play of multiple internal factors and extrinsic factors
[1,2]. DNA binding and induction of mutations in
cancer-susceptibility genes are considerable mechanisms
of tumour initiation. It is also reported that over 80% of
cancer deaths in Western industrial countries can be
attributed to extrinsic factors such as tobacco, alcohol,
diet, infections and occupational exposures [1].
Alterations in multiple genes expression in cancer lead
to dysregulation of the normal cellular programme for
cell division, differentiation, apoptosis and proliferation.
This results in an imbalance of cell replication and cell* Correspondence: yjzhan2011@gmail.com
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reproduction in any medium, provided the ordeath, which favours growth of a tumour cell population
[3,4]. Clinically, cancer appears to be many different dis-
eases with different phenotypic characteristics. As cancer
progresses, the genetic drift in the cell population pro-
duces cell heterogeneity with characteristics including
cell antigenicity, invasiveness, metastatic potential, rate
of cell proliferation, differentiation state and response to
chemotherapeutic agents [5,6].
In the past 10 years, a number of radiotherapy and
chemotherapy strategies available to treat cancer have
increased [7]. Much of medical practice is based on
standards of care. These interventions are based on
knowledge and experience from the different levels of
evidence generated by epidemiological and clinical stud-
ies or evidence-based medicine [8,9]. However, large ran-
domised studies are designed to determine approach for
the average populations, but not for specific individuals,
which results in the therapeutic model ‘the same thera-
peutic strategy for the same type of disease’. In addition,
basic scientists and clinicians have raised a lot of funda-
mental questions regarding identification of the causess is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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characters in tumour susceptible group, predictive meas-
urement used, the basic mechanisms of malignant trans-
formation of cells, possibility of the use of the gene
expression patterns of cancer cells to identify targets for
cancer diagnosis or therapy, the suitability of the use of
the common single parameter treatment measurement
for all tumour patients, and the necessary or appropriate
type of clinical trials for personalised therapeutic modal-
ity. Based on these questions, we propose the use of the
multi-parameter systematic strategy to predict, prevent
and personalise the treatment of a cancer. The multi-
parameter systematic strategy for predictive, preventive
and personalised medicine (PPPM) in cancer was ini-
tially conceived by the Zhan and Desiderio [10]; this
concept was addressed by XZ as a keynote speaker and
panellist at the first EPMA-World Congress 2011 and
was collected into the post-meeting report of the first
EPMA-World Congress 2011 (or called “EPMA White
Paper”) [11].
Pathophysiological basis of multi-parameter systematic
strategies for PPPM in cancer
From a clinical point of view, cancer is a large group of
diseases that vary in their age of onset, rate of cell prolif-
eration, state of cellular differentiation, invasiveness,
metastatic potential, diagnostic detectability, response to
treatment and prognosis [12-14]. From a molecular bio-
logical point of view, cancer is a kind of gene disease
and results in a series of molecular changes, which is
correlated with signal transduction system, cell cycle,
differentiation and apoptosis [15,16].
Not only one intracellular signal pathway is involved in
the molecular mechanisms of a cancer [17]. For example,
several research groups have demonstrated that phosphoi-
nositide 3-kinase (PI3K/Akt), mitogen-activated protein
kinase (MAPK) and signal transducer, and activator of
transcription 3 (STAT3) pathways were activated in
obesity-associated colon cancer. Mammalian target of
rapamycin (mTOR), a down-stream of both PI3K/Akt and
MAPK, is highly activated [18]. Activated mTOR in turn
inhibits the PI3K/Akt pathway and further activates the
STAT3 pathway [19]. Elucidation of multiple signal path-
ways has therapeutic implications. The activity of PI3K/
Akt may increase significantly if mTOR is inhibited be-
cause of the feedback inhibition of mTOR on PI3K activity
[20]. Thus, it is highly important to simultaneously inhibit
both mTOR and PI3K in the treatment of obesity-
associated cancer. Thus, a number of small molecules
which both inhibit PI3K and mTOR have been developed
[21]. They include BEZ-235, SF1126 and XL765, which
are more effective than single inhibitors of PI3K or mTOR
in cancer therapy. SF1126 and XL765 has been used for
phase I clinical trials, and BEZ-235 has been used in phaseII clinical trials in the treatment of several cancers [22-26].
Thereby, traditional investigation focusing on single-
molecule biomarker or target in tissue or plasma for can-
cer prediction and prevention is an unrealistic assumption.
Not one single-parameter can resolve an entire problem,
or sometimes, one parameter is unable to resolve a prob-
lem at all. Multiple inhibitors could provide a novel ap-
proach to inactivate signal pathways and are likely to have
a better therapeutic effect than any one single-inhibitor.
Tumour heterogeneity is another important character of
malignant tumour [10,27-30]. Heterogeneity is observed
in very part of the tumour, not only in the same tumour
among different patients, but also in all tumour progres-
sion stages of the same individual patients [31]. The gen-
etic instability of tumour cell is an important factor of
tumour progression and heterogeneity, and results in som-
atic mutation which appears as an increasing phenotypic
variability of the tumour cell group [32,33]. However, most
treatment schemes were designed according to the doc-
tor’s experience. The therapeutic model ‘the same thera-
peutic strategy for the same type of disease’ commonly
existed so its curative effect cannot achieve the expected
purpose. Heterogeneity was often ignored in tumour treat-
ment. Tumour cell genetic instability often appears many
cell subsets with different biology characteristics [34,35].
These cells subsets have different sensitivity to various
therapeutic agents [36]. Some tumour gene expression
resulted in the treatment resistance. Moreover, the treat-
ment factor itself (such as radiotherapy and chemotherapy)
is also a mutagen that promotes formation of new cell sub-
sets in tumour progression especially when the treatment is
not suitable. Obviously, tumour heterogeneity has greatly
trapped the tumour treatment. On the other hand, the indi-
vidual differences between tumour patients, such as the
function of liver and kidney, age, physical condition and
personal lifestyle factors, are also another important factor
which impacts on the tumour treatment [37].
Tumour heterogeneity and individual difference are
actually derived from individualised (or personalised)
variations. No two completely same individuals exist in
the world. Variations are involved in each aspect of
healthcare (Figure 1). Human healthcare includes three
main stages: prediction/prevention, early stage diagno-
sis/early-stage therapy and late-stage diagnosis/late stage
therapy. The assessment of preventive response will
measure the efficacy of preventive intervention. The as-
sessment of therapeutic response, namely, prognostic
assessment, will measure the efficacy of therapeutic
intervention. Towards the goal of human health, the
prediction/prevention is the most important stage
among the three stages because it will keep one in the
status of no disease. Early stage diagnosis/therapy is the
better strategy to halt the development of cancer when
















Personalised (or individualised) variations
Personalised (or individualised) variations
Prognosis
assessment
Figure 1 Personalised (or individualised) variations are involved
in each aspect of healthcare.
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wards the goal of prediction/prevention and early stage
diagnosis/therapy. Late stage diagnosis/therapy is com-
monly called clinical diagnosis and treatment of a
cancer. However, even though during the late stage diag-
nosis/therapy, variations are still involved in this stage;
for example, radiotherapy and chemotherapy will vary
among individuals.
In summary, cancer is a complex disease and can be
initiated by various factors [1,2]. Tumour progression is
accompanied by multitude of changes in metabolisms
and cell signal pathways [17]. Tumour heterogeneity and
individual differences, or called individualised variations,
also hamper cancer healthcare. It is difficult for one to
use traditional single-factor strategy to perform PPPM
practice in cancer healthcare. Thereby, these factors de-
termine the necessity of the multi-parameter systematic
strategy for PPPM in cancer.
Novel strategies and technologies for multi-parameter
systematic strategies for PPPM in cancer
Chemotherapy and radiotherapy are the main thera-
peutic schemes for cancer in clinic [38,39]. The major
obstacles of cancer chemotherapy are the development
of drug resistance and the severe side effects [40]. Due
to the modest tumour specificity of many anticancer
drugs, normal tissues are also damaged. This prevents
the application of sufficient high doses to eradicate less
sensitive tumour cell populations. Thereby, tumours de-
velop drug resistance that leads to treatment failure and
fatal consequences for patients. Cancer radiotherapy also
appears to develop radiation resistance and severe side
effects [41] in patients. The efficacy of chemotherapy
and radiotherapy of cancer extensively varies among
individuals. Moreover, the prediction/prevention and
early stage diagnosis/therapy in the molecular levels of
cancer remain important and difficult issues. In addition,
individualised variations are involved in each stages ofcancer healthcare, which leads to the complexity of
PPPM in cancer. Novel strategies and technologies such
as ‘omics’ and systems biological techniques would be of
great benefit for PPPM in cancer.
Genomics
Recent genomics technical breakthroughs have facilitated
sequencing of the whole genome, genome-wide methyla-
tion analysis and transcriptome arrays in individual
patients [42,43]. High-throughput sequencing now allows
one to sequence more numbers of study patients and will
facilitate for a therapeutic decision [42-44]. Previous high-
throughput studies on gene expression profiling and epi-
genetic alterations in tumour cells have generated large
amounts of data. The complexity of these data may result
from the heterogeneity of cell material that will provide an
averaging of results among tumour cells, stroma, endothe-
lium and blood cells, and lead to longstanding genomic
instability [45,46]. In turn, DNA studies, while more de-
finitive in the presence of clonal tumour cells, have been
hampered by the inability to readily detect unknown
lesions; polymerase chain reaction amplification technolo-
gies can usually only arrest known suspects but fail to
identify culprits among the general population of genes
that have not been incriminated by previous evidence. An-
other weakness is the lack of a proper reference to the
same individual’s normal tissues. Yet truly predictive or in-
formative studies have proven significantly more difficult
than originally anticipated.
Transcriptomics
Transcriptomics has been used to describe the global
mRNA expression of a particular tissue, yielding infor-
mation about the transcriptional differences between
two or more states [28,47,48]. Understanding the tran-
scriptomics is essential for interpreting the functional
elements of the genome and revealing the molecular
constituents of cells and tissues and also for understand-
ing cancer development.
Microarray allows analysis and quantification of the
entire transcriptome profile of an organism [49].
Hybridisation-based approaches typically involve incu-
bating fluorescently labelled cDNA with custom-made
microarrays or commercial high-density oligonucleo-
tide microarrays. Specialised microarrays have also
been designed; for example, arrays with probes span-
ning exon junctions can be used to detect and quantify
distinct spliced isoforms [50]. Genomic tiling microar-
rays have been constructed and allowed the mapping
of transcribed regions to a very high resolution, from
several base pairs to approximately 100 bp [51,52].
Hybridisation-based approaches are high throughput and
relatively inexpensive. A vast literature has accumulated
on the use of microarray profiling in cancer diagnosis and
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sion profiling can detect lymph node metastases for pri-
mary head and neck squamous cell carcinomas [53].
Combining transcriptional and metabolic data from the
same breast carcinoma sample contributes to a more
refined subclassification of breast cancers as well as
reveals relations between metabolic and transcriptional
levels [54]. Thus, microarray technology is a powerful re-
source for transcriptomes development in cancer.
However, these methods have several limitations,
which include reliance upon existing knowledge about
genome sequence, high background levels owing to
cross-hybridisation [55,56] and a limited dynamic range
of detection owing to both background and saturation of
signals. Moreover, comparing expression levels across
different experiments is often difficult and can require
complicated normalisation methods.
Proteomics
Proteomics mainly applies to the identification, character-
isation and quantitation of the protein in a defined system
(organelle, cell, tissue, biofluid or whole organisms)
[57-59]. Due to its ability to detect a large number of pro-
teins in a short period of time, proteomics has been con-
sidered as a powerful tool for the study of human tumour
[60]. The commonly used quantitative proteomic method-
ologies are (1) gel-based, two-dimensional polyacrylamide
gel electrophoresis [28,57,61,62] and two-dimensional dif-
ference in-gel electrophoresis [63,64] and (2) ‘gel-free’
isotope-tagging/labelling technologies, including isotope-
coded affinity tagging [65,66], stable isotope labelling with
amino acids in cell culture [67], proteolytic 18O labelling
[68,69] and stable isotope-tagged amine-reactive reagents
(iTRAQ) [70-73] and more recently, “label-free” mass
spectrometry (MS)-based proteomics [74,75]. In general,
gel-free methods can address many of the shortcomings of
gel-based approaches, which is tedious and inefficient in
resolving proteins that are lowly abundant, insoluble or
large (>200 kDa) [57]. Gel-free methods have rapidly been
incorporated in proteomic laboratories, since they are able
to overcome many of the limitations of gel-based
approaches [57,76]. These main technological tools are
typically followed by identification of interest spots using
MS analysis which allows highly sensitive and high-
throughput identification of proteins/peptides and post-
translational modifications. Briefly, a large variation of MS
technologies is currently available, which evolved from
electrospray ionisation (ESI) and matrix-assisted laser de-
sorption/ionisation (MALDI) to a new generation of mass
analysers, such as hybrid quadrupole time-of-flight (TOF)
and tandem time-of-flight (TOF/TOF) instruments
[77,78]. While newer and higher capacity MS technolo-
gies, such as LTQ-FT-MS and orbitrap type of analysers,
are being developed [79,80], the most commonly used MStechnologies include MALDI-TOF, SELDI-TOF and ESI-
MS/MS.
By using these technologies, a lot of biomarkers and
drug targets in cancer have been discovered. For example,
Zhan et al. have identified proteins, including pituitary
hormones, cellular signals, enzymes, cellular-defence pro-
teins, cell structure proteins and transport proteins in
human pituitary adenoma using 2-DE with MALDI-TOF
and liquid chromatography-electrospray ionisation-quad-
rupole ion trap (LC-ESI-Q-IT) [28,57,81,82]. The phos-
phorylation sites at Ser-77 and Ser-176 of human growth
hormone were also found in the normal (control) pituitary
and in adenomas [83]. Secretagogin was found to be a po-
tential biomarker for human nonfunctional pituitary aden-
oma [57,82]. GSTP1, HSPB1 and CKB were found to be
novel potential biomarkers for early detection of lung
squamous cell carcinoma by using iTRAQ-tagging com-
bined with two-dimensional liquid chromatography tan-
dem MS analysis, while GSTP1 down-regulation is
involved in human bronchial epithelial carcinogenesis
[84]. The protein profiles in response to epidermal growth
factor (EGF) treatment in ovarian cancer cells were ana-
lysed using iTRAQ labelling and mass spectrometry [85].
One of the differentially regulated proteins, lysosomal-
associated membrane protein-1, in different stages of
epithelial ovarian cancers was found to be a promising
biomarker in understanding the progression of EGF-
stimulated ovarian cancers and to be useful in the predic-
tion of treatment responses involving tyrosine kinase
inhibitors or EGF receptor monoclonal antibodies [85].
It is also evident that current proteomic technologies
are biased towards high-abundant proteins. A current
challenge is, thus, the study of low-abundant proteins [57].
Because many proteins do perform their biological activity
as a partner of protein groups, another area receiving
increasing attention is the protein-protein interaction ana-
lysis and cell signal pathway. The identification of protein-
protein interactions is important to understand the
mechanisms of signal transduction and establishing intra-
cellular signalling networks [86,87].
Metabolomics
Metabolomics is useful to predict the effect of metabolic
pathways on anticancer drugs in tumours and patients
[88]. By means of metabolomic techniques, global sets of
low-molecular weight metabolites are measured as indi-
cators of physiological or pathological states. Large-scale
data obtained by metabolomic methods may contribute
to construct molecular interaction and gene regulatory
networks that are able to predict drug effects [89,90].
The development of drug resistance and severe side
effects leads to treatment failure and fatal consequences
for patients. Novel strategies to broaden the narrow
therapeutic range by separating the effective dose and
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ment of cancer chemotherapy.
The potential of ‘omics’ technologies for the prethera-
peutic screening of markers may help to identify the
best-tolerated and most effective treatment strategy at
optimal dose scheduling according to individual ‘omics’
fingerprints of each cancer and each patient.
Systems biology
The human genome project has catalysed two major
paradigm changes of systems biology and PPPM [91-93],
which dominate the twenty-first century biology and
medicine [94]. Life is a very complicated and systematic
phenomenon, which is not inherent in DNA, RNA, pro-
teins, carbohydrates or lipids but is a consequence of
their actions and interactions [95]. Only analysis of one
factor among them would not really reveal the essential-
ity of life and disease, which results in the difficulty in
fighting against disease. Thus, elucidation of their
actions and interactions must be necessary, which cata-
lyses the coming out of systems biology. Systems biology
is a comprehensive analysis of all the components of a
biological system at a given conditions, which needs an
interdisciplinary team of investigators who are also cap-
able of developing high-throughput technologies and
computational tools. The rapid development of ‘omics’
technologies, bioinformatics and computation biology
accelerates the development of systems biology, which,
in turn, revolutionises the traditional biology [95]. How-
ever, many technical challenges remain for systems biol-
ogy, including (a) data quality and standardisation of
‘omics’-based large-scale data, (b) the immaturity of net-
work biology, (c) the requirement of high-sensitivity
tools for detection and quantification of the concentra-
tions, fluxes and interactions of various types of mole-
cules at a given space and time, (d) the necessity of
miniaturised and automated microfluidics/nanotechnol-
ogy platforms that are capable of multi-parameter ana-
lyses of cell sorting and single cell gene and protein
profiling, (e) the need of imaging technologies that
enable the dynamic, spatial and multi-parameter mea-
surements within single cells, and (f ) even challenges
regarding fair credit and data ownership [95]. Systems
biology will be much improved with resolving those
challenges, which offers the great promise for the revo-
lution in the medicine practice [96]. Under the concept
of systems biology, the integration of ‘omics’ data, spe-
cific genetic traits and multi-parameter diagnostics
techniques will improve and form novel assessing proce-
dures of health and disease status, evolute the predictive
and preventive medicine and restrict personalised
medicine.
The rapid development and application of systems
biology in disease is reforming basic medical researchand clinical practice. In the future, medical researchers,
clinicians and patients will be equipped with a deluge of
personal information such as whole genome sequences,
transcriptomic and proteomic profiling of diseased tis-
sues, interactome network and periodic multi-analyte
blood testing of biomarker panels for disease and well-
ness [96]. This information will enable accurate predic-
tion and early diagnosis for a disease and personalised
treatment of a patient. Of course, ones are still at the dawn
of PPPM, the full implementation of which requires inte-
gration of basic and clinical researches through advanced
systems thinking and the employment of high-throughput
technologies in genomics, proteomics, nanofluidics,
single-cell analysis and computation strategies.
In summary, the development of ‘omics’ and systems
biology strategies and techniques catalysed one to con-
sider healthcare in a multi-parameter systematic angle.
The ‘omics’ produces high-throughput data at the gen-
ome (DNA), transcriptome (mRNA), proteome (protein)
and metabolomics (metabolite) levels. Systems biology
can systematically integrate those ‘omics’ data to form a
panel change of genes, proteins, metabolites and clinical
features to predict, prevent and personalise the treat-
ment of cancer (Figure 2). However, the question also
arises as to which particular cytostatic agent and which
combination of substances is most suited for an individ-
ual tumour. The concept of individualised therapy itself
traces back to the 1950s [97]. The statistical probability
of therapeutic success is well known for larger groups of
patients from clinical therapy trials. However, it is not
possible to predict how an individual tumour will re-
spond to chemotherapy. Although clinic-pathological
prognostic factors such as tumour size, lymph node and
far distance metastases are valuable for the determin-
ation of prognosis of larger cohorts, those are less help-
ful for the development of personalised therapy options.
With the current progress in molecular biology, the
practice of PPPM in the clinic needs a lot of work to do.
Here, an example is taken regarding the use of prote-
omic and transcriptomic variations for PPPM in human
nonfunctional pituitary adenoma. Proteomics and tran-
scriptomics studies were performed in human pituitary
adenoma [28,57,82]. A total of 56 differentially expressed
proteins and 284 differentially expressed genes were
identified in human nonfunctional pituitary adenomas
compared to control pituitaries (Figure 3) [28,57,82].
Only nine genes were found with significant consistent
changes at the mRNA and protein levels (Figure 3). A
phenomenon was observed that at the gene level, a gene
would not have a significant change, but at the protein
level, its corresponding protein has a significant change.
Also, at the gene level, a gene would have a significant
change, but at the protein level, its corresponding pro-
tein had an indistinctive change. It indicates that the
Genes
~25,000 genes






















Rate of cell proliferation
Differentiation state
Diagnostic detectibility
Response to treatment 
Figure 2 The contributions of ‘omics’ and systems biology to the practice of PPPM.
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complex genome and proteome system. The assumption
based on the traditional single gene and protein as a bio-
marker for a cancer healthcare is no reality. Actually, it
is very difficult for one to say that any single cancer-
specific gene and protein is found. But it would be
confident for one to say that a panel of genes/proteins
was discovered to be related to human pituitary aden-
oma. It is very dangerous for those researchers who as-
sume that the research failed without the discovery of
single specific gene and protein. The reality is that there are
a huge number of scientific publications regarding a single
gene and protein, and each publication emphasises that its
studied gene and protein are such important and specific
to a disease. However, in regard to how much of those so-
called specific gene and protein products contributed to
the resolution of a disease in the disease system could be a
doubt. Thus, from the angle of systems biology, four signifi-
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Comparative proteomics vs. Comparative transcriptomics 
Figure 3 Analysis of comparative proteomics vs. comparative
transcriptomics in human nonfunctional pituitary adenomas.
*Comparative proteomics found 251 differential gel-spots, 93
differential gel-spots were excised for MS characterisation, and 56
proteins were identified.associated with nonfunctional pituitary adenomas were dis-
covered including mitochondrial dysfunction, oxidative
stress, cell-cycle dysregulation and the MAPK-signalling
abnormality [10,17]. Therefore, we propose that the use of
a panel of genes/proteins as the biomarker would be more
reliable and significant for prediction, prevention and per-
sonalised treatment of cancer. Based on the concept of
multi-parameter systematic strategy, first, one should con-
sider the human pituitary adenoma as a whole body disease
then the targeted organs for proteomic variation analyses
should include not only pituitary tissues, but also body fluid
(cerebrospinal fluid and plasma). Figure 4 shows the contri-
butions of pituitary tissue proteomic variations and of
body-fluid proteomic/peptidomic variations to pituitary ad-
enoma. Second, no single technique is perfect to measure
the omic variation; one should consider the use of mul-
tiple techniques to measure the proteomic variations and
protein/peptide pattern variations. Figure 5 shows the use
of gel and non-gel methods to measure the pituitary ad-
enoma proteomic variations and the use of systems
biology techniques to denote the protein variation in
the network system. Figure 6 clearly shows the techni-
ques of body fluid protein/peptide pattern recognition
including the SELDI-TOF-MS-based protein pattern
recognition, the MALDI-TOF-MS peptide pattern rec-
ognition and tryptic-peptide pattern recognition; also,
protein/antibody microarray would be another useful
technique for multi-parameter systematic strategy of
PPPM in cancer.
Prospective thoughts regarding multi-parameter
systematic strategies for PPPM in cancer
Recent technological advances, combined with the devel-
opment of bioinformatics and systems biology tools, allow
Targeted organs of proteomic variation
Pituitary tissues
Body-fluid proteome/peptidome Tissue proteome
Cerebrospinal fluid (CSF) plasma
Tumour tissues: neurosurgery from patients
Control tissues: forensic anatomy from post-
mortem cardavers
Uncontrollable bias: gender, age, race, time 
of tissue acquisition, and some biochemical 
changes are not consistent.
Adenoma tissue: monoclonal in origin, and 
generally benign, contains a relatively pure 
cell population
Control mortem tissue: contains different 
types of cells, at least corticotrophs, 
somatotrophs, lactotrophs, thyrotrophs, and 
gonadotrophs, etc.
Bias: cell types are not consistent
Overcome: laser-capture microdissection
(LCM) 
Compared to the tissue proteome, the body-
fluid (CSF and blood) specimens don’t have 
those limitations.
The body-fluid specimens are much more 
accessible from patients and controls than 
the pituitary tissues
Body-fluid proteomic/peptidomic variations 
will lead to the development of an accurate 
predictive diagnosis and the measurement of 
interventional prevention and therapy 
response
Figure 4 Targeted organs that are used to analyse proteomic variations in human nonfunctional pituitary adenomas.
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approaches (i.e. genomics, transcriptomics, proteomics
and metabolomics). The rapid developments in omic tech-
nologies allow for a systematic investigation of genes, pro-
teins and metabolites occurring in a tumour. The search
for individual genomic, transcriptomic, proteomic and
metabolomic variations in tumour diseases will help ones
to better characterise the disease in each patient. The








2D DIGE is more useful to analyze precious s
LCM-enriched samples because it requires 
less protein amount and fewer gel-analysis 
procedure compared to 2DGE
Limitations: extremely acidic (pI < 3.5 or 4) 
/basic (pI > 7.5 or 8) proteins, extremely 
high-mass (>150kDa) or low-mass (<10 kDa) 
proteins, hydrophobic proteins
Gel methods can detect protein isoforms
Systems biology techniques: pathw
•Pathway analysis denotes each protein vari
•The recovery of the tumour-altered pathway
would contribute significantly to intervention
therapy
Figure 5 Techniques that are used to measure proteomic variations.tumour patients. However, these data are now not avail-
able to become integrated into clinical practice.
Here, a lot of problems exist since most of the re-
searches focus on single-molecule biomarker and a single
compound used for detecting a disease in clinic; however,
the reality is characterised by heterogeneity among
patients [10]. Cancer is initiated by numerous factors and
causes a range of different molecular changes. The pituit-









Non-gel methods effectively detect low-
abundance proteins, extremely acidic/basic 
proteins, and low/high-mass proteins
Limitations: protein isoforms
ay network analysis
ation within a pathway network system
 system to the normal pathway system 
al prevention and effective chemical 
Techniques to measure body-fluid protein/peptide-pattern variation
Protein pattern-recognition Peptide pattern-recognition
SELDI-TOF-MS MALDI-TOF-MS
The plasma (or CSF) peptides 
from tumours and controls are 
individually enriched and isolated 
with reverse phase magnetic 
beads, and applied on a MALDI 
plate. The peptides on the plate 
are scanned with TOF-MS. The 
MS spectra are compared to 
determine the differential pattern 
of MS peaks to discriminate 
tumours and controls.
Serum or CSF samples 
from tumours and controls 
are individually applied to a 
SELDI chip. The retained 
proteins on the chip are 
detected with TOF-MS. The 
MS spectra are compared 
to determine the 
differential pattern of MS 
peaks to discriminate 
tumours and controls.
The body-fluid samples 
are first digested with 
trypsin, and analysed 
with MALDI-TOF-MS. 
The MS spectra are 
compared to determine 
the differential tryptic-
peptide pattern of MS 





Those signature proteins/peptides or their antibodies could be immobilised 
onto a microchip for the prediction, diagnosis, and the measurement of 
preventive and therapeutic responses
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Figure 7 To realise PPPM is a systematic engineering and
needs multiple supports.
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predict and diagnose acromegaly and prolatinoma, re-
spectively. However, a large number of acromegaly and
prolactinoma patients are still detected at an advanced
stage. For the nonfunctional pituitary adenomas, no blood
hormone levels are elevated, almost all nonfunctional pitu-
itary adenomas are diagnosed at a late stage, and no mo-
lecular indices measure the therapy response and
prognosis. Multiple-parameter biomarkers from serum or
cerebrospinal fluid (CSF) will resolve these problems in
prediction, prevention and personalised treatment and as-
sessment of a nonfunctional pituitary adenoma. Several
promising multi-parameter strategies from serum or CSF
proteomes and peptidomes might meet those require-
ments and include protein/peptide pattern diagnostics,
protein microarrays and an antibody microarray as
described previously.
Authors agree how important to study the structure
and functions of a single protein/gene. However, perso-
nalised variations are involved in each aspect of health-
care as shown in Figure 1. For prediction, early stage
diagnosis, and personalised treatment of a cancer, ones
are encouraged to consider it through a multi-parameter,
systemic angle of PPPM.
Besides technical support such as the further develop-
ment of a large amount of basic, clinical, bioinformatics
and instrumental methods, the PPPM needs a lot of
work to do (Figure 7): (a) a reliable biobank including
standard sample collection method, standard cell separ-
ation method, authentic and detailed patient data; (b)
government support such as policies and financial sup-
port; (c) education support which helps people knowwhat is PPPM and accept it; (d) industrial support which
transforms the research results to products and (e) in-
surance support including policies and benefit. There-
fore, to realise PPPM is a systematic engineering and
needs multiple pertinent supports. In addition, this com-
prehensive proposal needs to be supported by not only
different individual research programmes but also inter-
national efforts such as the EPMA [11].
Recent findings have begun to improve analysis condi-
tions in all of these areas, promising that the definition
of new biomarkers will become much more precise. For
RNA and protein characterisation, the choice of the
proper phenotype to be analysed has begun to improve
the feasibility of target identification in relevant cell
populations. Enrichment technologies derived from
other areas of stem cell research have allowed to highly
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capable of self-renewing growth and forming metastases
from those cells that form the bulk of the tumour but
never metastasise.
Two predictive markers (ER and HER2) for breast can-
cer are taken here for example. To date, these two mar-
kers have been established to predict efficacy of either
endocrine or HER2-targeted therapy in breast cancer.
The treatment of HER2-positive breast cancer is cur-
rently most advanced in terms of personalised breast
cancer therapy. Besides the monoclonal antibody trastu-
zumab, further HER2-targeted drugs, namely tyrosine
kinase inhibitors (TKIs) and other monoclonal anti-
bodies, have been developed to overcome treatment re-
sistance against trastuzumab. Lapatinib, a TKI against
HER2 and HER1, disrupts the HER2 signalling pathway
via inhibition of the intracellular tyrosine kinase activity.
Lapatinib is active after trastuzumab failure and can en-
hance the efficacy of trastuzumab alone [98]. Further
HER2-targeted agents such as pertuzumab or T-DM1
also have the same efficacy on breast cancer therapy.
Personalised treatment, however, does not mean to
target all resistance mechanisms in all patients, but ra-
ther the identification of the right target agent or com-
bination of agents for each individual patient. Thus, the
comprehensive biomarker programmes to elucidate the
specific mechanisms of resistance in individual patient
are needed. Afterwards, an ever-growing list of new tar-
geted agents, according to comprehensive biomarker,
will be greatly effective for cancer therapy. The art of
PPPM will be to select the right treatment for the right
patient at the right time as opposed to the ‘one size fits
all’ concept. In this respect, the integration of multiple
omic results and procedures seems necessary. Therefore,
an emerging challenge is the integration of the huge
amount of data generated and the standardisation of the
procedures and methods used. Functional data integra-
tion will lead to answers to unsolved questions and,
hopefully, will be applicable to clinical practice and man-
agement of patients.
To establish PPPM for clinical practice, the efficient
and fast bioinformatics and systems biology pro-
grammes are required to filter the relevant data useful
for clinicians to guide their treatment decisions. Future
cancer patients will receive a comprehensive genomic
and proteomic analysis of their tumours that will allow
oncologists to tailor therapies aimed at specific mo-
lecular lesions for maximum clinical benefit with min-
imal treatment-related toxicity. Not all of these
findings will be useful for every patient; but step by step,
knowledge of individual molecular lesions will lead to the
development of surgical, radiological and medical
approaches to provide an oncology patient with persona-
lised medicine.Conclusions
The development of molecular biology and systems biol-
ogy technologies to analyse DNA, RNA, protein and me-
tabolite provides potential contributions to healthcare
practice at both levels of local and holistic therapies of a
tumour patient. These approaches have the potential to
fulfill the promise of delivering the right dose for the
right indication to the right patient at the right time.
Importantly, PPPM offers the opportunity to increase
therapeutic efficacy by targeting the genomic variations
or proteomic variations driving tumour behaviour while,
at the same time, decreasing inadvertent toxicity due to
altered drug metabolism encoded by the patients’ genetic
background. Besides molecular biology technologies de-
velopment, the practice of PPPM also needs all aspects
of support including education, government, reliable
biobanks, industry and insurance. The traditional single-
factor strategy should be shifted to the multi-parameter
systematic strategy for PPPM in cancer.
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